Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cholecalciferol - CKD Clear all

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
Interventions: PLS240, Standard of Care; Drug · Combination Product
Lead sponsor: Pathalys Pharma; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Etelcalcetide, Standard of Care; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more

Conditions: Vitamin D Deficiency, Renal Failure Chronic Requiring Hemodialysis
Interventions: Ergocalciferol, Placebo; Drug
Lead sponsor: Albany College of Pharmacy and Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Albany, New York • Clifton Park, New York • Saratoga Springs, New York + 1 more

Conditions: End Stage Renal Disease
Interventions: Not listed
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington

Conditions: Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions: Hectorol (doxercalciferol capsules), 0.5mcg; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more

Conditions: Chronic Kidney Disease, Vitamin D Deficiency
Interventions: Cholecalciferol, Placebo; Drug
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions: CTA018 Injection; Drug
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more

Conditions: Chronic Kidney Disease
Interventions: Paricalcitol, Placebo; Drug
Lead sponsor: Amy Barton Pai; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Albany, New York

Conditions: Pruritis
Interventions: 50,000 Units Ergocalciferol, Placebo; Drug
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Bethpage, New York • Mineola, New York

Conditions: Chronic Kidney Disease Stage 3 and 4
Interventions: Ergocalciferol, Cholecalciferol; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Paricalcitol, Ergocalciferol; Drug
Lead sponsor: Salem Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salem, Virginia

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Contrast Enhanced Ultrasonography; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Renal Insufficiency, Chronic, Kidney Failure, Chronic
Interventions: Vitamin D; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 21 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: End-Stage Kidney Disease
Interventions: Zemplar (paricalcitol injection), Calcijex; Drug
Lead sponsor: Abbott; Industry
Eligibility: 20 Years and older
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 60
States / cities: Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more

Conditions: Chronic Renal Insufficiency, Proteinuria
Interventions: Vitamin D, Placebo; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions: Cinacalcet hydrochloride, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 28 Days to 2189 Days
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 17
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Chronic Kidney Disease, Anemia of Chronic Disease
Interventions: Oral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: End Stage Renal Disease
Interventions: cholecalciferol, placebo; Dietary Supplement
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions: CTAP201 Injection, Doxercalciferol; Drug
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more

Conditions: Secondary Hyperparathyroidism-Chronic Kidney Disease
Interventions: Doxercalciferol (GZ427397), Calcitriol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more

Conditions: Chronic Kidney Disease
Interventions: D6-25-hydroxyvitamin D3; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Kidney Disease
Interventions: cholecalciferol, doxercalciferol, placebo; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients

Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

Effect of Vitamin D Supplementation on Balance in CKD

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease

Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation

The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.